XOMA CORPORATION

Analyst Reco. XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Market Closed - Nasdaq Other stock markets 02:00:01 18/05/2024 am IST			5-day change	1st Jan Change
25.1 ^USD	0.00%		-0.08%	-0.08%

09/05	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT
09/05	XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	29/04	MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating	09/23/09	MT
XOMA : Wedbush Suspended Coverage on XOMA	11/21/11	MT
XOMA : HC Wainwright Adjusts XOMA's Price Target to $69 from $56, Keeps Buy Rating	08/21/08	MT
XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating	09/21/09	MT
Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	07/21/07	MT
XOMA : Wedbush Downgrades XOMA to Neutral From Outperform, Adjusts PT to $22 From $41	07/21/07	MT
XOMA : Aegis Capital Starts XOMA at Buy with $20.68 Price Target	29/21/29	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $41 From $36, Citing Iscalimab, Cetrelimab Projections; Outperform Rating Kept	19/21/19	MT
XOMA : Wedbush Adjusts XOMA's Price Target to $36 From $29 on Vicineum Sales Forecast, Keeps Outperform Rating	27/20/27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW